Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin decreases hepatic glucose production and enhances peripheral insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, raising incretin hormone levels that stimulate insulin release only when blood glucose is elevated. The dual mechanism provides additive glucose‑lowering effects without causing excess insulin secretion.

The specific dose of Maymetsi is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety of Maymetsi in pregnancy and lactation has not been fully established. Metformin is sometimes used during pregnancy under specialist supervision, whereas sitagliptin lacks sufficient data. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider.

To request Maymetsi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maymetsi offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitising and incretin‑enhancing actions in a single tablet. Compared with metformin alone, it adds greater post‑prandial glucose control; compared with DPP‑4 inhibitor monotherapy, it includes the well‑established benefits of metformin on fasting glucose and weight neutrality.

Maymetsi tablets should be stored at room temperature, below 25 °C, in the original blister pack or bottle. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Maymetsi is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water. Patients should adhere to the dosing schedule prescribed by their clinician and not crush or split the tablet unless advised.

The most serious risks include lactic acidosis from metformin, which is rare but life‑threatening, and severe hypoglycaemia, especially when used with other glucose‑lowering agents. Pancreatitis and allergic reactions are also rare but require immediate medical attention if symptoms arise.

Maymetsi is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and those receiving iodinated contrast media without appropriate renal monitoring. Clinicians should evaluate each patient’s medical history before prescribing.